Melatonin is a timing signal, not a sleeping pill. Used at the wrong time it shifts the rhythm the wrong way.
Jet lag is a circadian problem, and the treatment is circadian, which is why melatonin helps and why it does not work the way people expect.
Melatonin is a timing signal. It is released by the pineal gland in the evening in response to darkness and it tells the body that night has begun. Taking it at the destination's bedtime for the first few nights after arrival advances the rhythm and reduces jet lag, and this is the best-established use. The timing is the active ingredient, not the dose — the trials used low doses (0.5-3 mg), higher doses are not clearly better, and taking it at the wrong hour shifts the rhythm in the wrong direction and makes things worse. It is not a general sleeping pill and it does not treat ordinary insomnia in the way a hypnotic does.
Light is the other lever and it is stronger than the tablet. Light is the dominant zeitgeber — the signal that sets the clock — and the rule is that light in the biological morning advances the clock and light in the biological evening delays it. Practical translation for travel: seek morning light at the destination and avoid bright light in the destination's late evening. For an eastward trip (which is harder) you want morning light; for a westward trip you want evening light. Getting this backwards extends the jet lag rather than shortening it.
The other measures. Shift the sleep schedule before travelling where the trip is long; hydrate; avoid alcohol on the flight, which fragments the second half of the night and dehydrates; eat at the destination's mealtimes; and get outside in daylight on arrival rather than napping in a dark room.
Shift work is the same problem chronically. Rotating shifts, and especially backwards rotation, produce a persistent circadian misalignment that is associated with metabolic and cardiovascular risk. The measures with evidence are forward-rotating schedules where the employer allows it, strategic napping before a night shift, bright light during the shift and darkness on the way home (sunglasses, a dark bedroom), caffeine early in the shift rather than late, and consistent sleep timing on days off where possible. Melatonin before a day sleep can help, with the same timing caveat. None of this removes the health cost of long-term night work; it reduces it.
What not to do. Do not take a large melatonin dose at a random time. Do not use alcohol as a sleep aid on a flight. Do not use sedating antihistamines to force sleep across time zones and then drive at the destination.
Meta-Analysis2025Sleep medicine reviews
Effects of sleep hygiene education for insomnia: A systematic review and meta-analysis.
The majority of included trials (85.71 %) had a high overall risk of bias, and the remaining had "some concerns." Future work is encouraged to generate robust evidence through the development of well-designed SHE as an examined intervention for insomnia that involves process evaluation and treatment fidelity.
PubMed 40449065 ↗
Meta-Analysis2024Journal of pineal research
Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review of Randomized Controlled Trials and Dose-Response Meta-Analysis.
Our results suggest that advancing the timing of administration (3 h before the desired bedtime) and increasing the administered dose (4 mg/day), as compared to the exogenous melatonin schedule most used in clinical practice (2 mg 30 min before the desired bedtime), might optimize the efficacy of exogenous melatonin in promoting sleep.
PubMed 38888087 ↗
Meta-Analysis2024Clinical psychology review
Network meta-analysis examining efficacy of components of cognitive behavioural therapy for insomnia.
The current results suggest that sleep restriction therapy and stimulus control therapy are the most effective components of CBT-I.
PubMed 39504928 ↗
Meta-Analysis2024Journal of affective disorders
Cognitive behavioral therapy for insomnia to treat major depressive disorder with comorbid insomnia: A systematic review and meta-analysis.
This meta-analysis indicates that CBT-I has significant effects on depressive symptoms beyond the sleep domain among people with MDD.
PubMed 39242039 ↗
Meta-Analysis2024JNCI cancer spectrum
Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis.
CBT-I is supported as a first-line treatment for insomnia in cancer survivors, with significant benefits observed across sleep and non-sleep outcomes.
PubMed 38781520 ↗